The Asia Pacific Nanomedicine Market size is forecasted to be worth USD 56.10 billion by 2025 from USD 26.37 billion in 2021, registering a CAGR of 16.3% from 2021 to 2026.
The major factors driving the APAC nanomedicine market are the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. Also, the growing demand for medicine increases the demand for nanomedicine for treating various kinds of diseases. In addition, the ever-increasing population is significantly contributing to the Nanomedicine market growth as the older people are more suspectable to various chronic disorders such as diabetes, diseases, and increasing the prevalence of orthopedic diseases. Furthermore, the technological advancements for developing advanced treatments and medications are expected to boost the market growth.
On the other hand, the rising initiatives by the government and private organizations for creating awareness among the people through medical tourism are positively expected to influence market growth. Moreover, the increasing investments and fundings from the government and non-government in research and development activities for manufacturing novel and efficient drugs for treating various kinds of ailments as well as with the increase in rising awareness for developing sustainable medical and healthcare infrastructure in the region is increasing the growth of the APAC nanomedicine market.
However, the increase in the treatment and procedures cost and lack of awareness and knowledge about nanomedicine treatment are expected to restrain the market growth. Also, the lack of skilled and trained professionals and strict government rules and regulations limit the market growth. Furthermore, due to the adverse effects of medicines and treatments, rigorous regulatory processes for approving items before releasing them might impede the development of the nanomedicine market in the APAC region.
This research report on the APAC nanomedicine market has been segmented and sub-segmented into the following categories:
By Product:
By Disease Type:
By Nanomolecule Type:
By Country:
Regional Analysis:
Analysts at MarketDataForecast predicted, Asia pacific is one of the most lucrative regions for nanomedicine and will grow exponentially during the forecast period. There is a high incidence of cancer and cardiovascular diseases in the Asia Pacific due to the large senior population. In addition, growing health awareness and increasing healthcare expenditure are also driving the market growth.
China accounted for the largest share of the APAC nanomedicine market in 2020, and it is anticipated to register an exponential share during the forecast period. The growing population with the rising prevalence of chronic diseases such as cancer and cardiovascular diseases is majorly driving the growth of the market in the country. In addition, the increasing demand for drugs for life-threatening diseases is increasing the demand for nanomedicines in the market.
In this region, China is dominating the market due to an increase in the rising prevalence of chronic diseases and cardiovascular diseases among the people, which India follows as these countries have experienced a large number of cardiovascular patients in recent years, which is uplifting the growth of the nanomedicine market.
Similarly, India is one of the fastest-growing countries in the Asia Pacific region. The Nanomedicine market is projected to witness a considerable share during the forecast period. The increase in the competition between the players and increasing investments by the government and non-government are encouraging the growth of the nanomedicine market. As the government has also been focusing on research and development activities for the manufacturing of new drugs and medications
Japan, on the other hand, is estimated to grow at a healthy CAGR due to an increase in the technological advancements for developing advanced medications and treatment with the rising initiatives in the growing healthcare and medical awareness among the people with the rise in the well- established health care infrastructure is triggering the growth in the market.
KEY MARKET PLAYERS:
Companies playing a pivotal role in the APAC nanomedicine market profiled in the report are Johnson & Johnson, Merck & Co, Pfizer, Abbott Laboratories, GE Healthcare, Celgene Corporation, Nanosphere, Inc, Gilead Sciences, Hoffmann-La Roche, Nanospectra Biosciences, and Arrowhead Pharmaceuticals.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Diagnostic Imaging
5.1.3 Regenerative Medicine
5.1.4 Drug Delivery
5.1.5 Implants
5.1.6 Vaccines
5.1.7 Others
5.1.8 Y-o-Y Growth Analysis, By Product
5.1.9 Market Attractiveness Analysis, By Product
5.1.10 Market Share Analysis, By Product
5.2 Disease Type
5.2.1 Introduction
5.2.2 Cardiovascular Diseases
5.2.3 Neurological Diseases
5.2.4 Ophthalmological Diseases
5.2.5 Infectious Diseases
5.2.6 Immunological Diseases
5.2.7 Orthopedic Disorders
5.2.8 Oncological Diseases
5.2.9 Others
5.2.10 Y-o-Y Growth Analysis, By Disease Type
5.2.11 Market Attractiveness Analysis, By Disease Type
5.2.12 Market Share Analysis, By Disease Type
5.3 Nanomolecule Type
5.3.1 Introduction
5.3.2 Nanotubes
5.3.3 Nanoparticles
5.3.4 Nanodevices
5.3.5 Nanoshells
5.3.6 Others
5.3.7 Y-o-Y Growth Analysis, By Nanomolecule Type
5.3.8 Market Attractiveness Analysis, By Nanomolecule Type
5.3.9 Market Share Analysis, By Nanomolecule Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Disease Type
6.1.3.4 By Nanomolecule Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Disease Type
6.1.4.4 By Nanomolecule Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Disease Type
6.1.5.4 By Nanomolecule Type
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck & Co
8.3 Pfizer
8.4 Abbott Laboratories
8.5 GE Healthcare
8.6 Celgene Corporation
8.7 Nanosphere, Inc
8.8 Gilead Sciences
8.9 Hoffmann-La Roche
8.10 Nanospectra Biosciences
8.11 Arrowhead Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
